The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies-Reference-Cited by-同舟云学术

The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies

Published:2020-09-03 Issue:11 Volume:19 Page:1497-1504
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cai Yuwen¹²,Shi Weinan³,Xu Gaosi¹

Affiliation:

1. Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Jiangxi, China

2. Grade 2016, Clinical Medicine, The Second Clinical Medical College of Nanchang University, Jiangxi, China

3. Grade 2016, Clinical Medicine, The First Clinical Medical College of Nanchang University, Jiangxi, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1817378

Reference32 articles.

1. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

2. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

3. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

4. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated analysis for treatment scheme of sodium–glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study;Scientific Reports;2023-04-12

2. Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives;Diabetes mellitus;2022-06-08

3. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers;Diabetes & Metabolism;2022-03

4. Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials;Endocrinology, Diabetes & Metabolism;2021-10-12

5. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies;Diabetes Epidemiology and Management;2021-07